R1 RCM Inc. (NASDAQ:RCM) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of R1 RCM Inc. (NASDAQ:RCM) have been assigned an average rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $15.83.

A number of analysts have weighed in on the company. Barclays reiterated an “equal weight” rating and set a $14.00 price target on shares of R1 RCM in a report on Wednesday, February 28th. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 target price on shares of R1 RCM in a research note on Wednesday, April 10th. Royal Bank of Canada restated an “outperform” rating and issued a $19.00 target price on shares of R1 RCM in a research note on Tuesday, June 11th. Guggenheim reduced their target price on R1 RCM from $17.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, April 5th. Finally, SVB Leerink initiated coverage on R1 RCM in a research note on Monday, February 26th. They issued an “outperform” rating and a $14.00 target price for the company.

Institutional Investors Weigh In On R1 RCM

A number of hedge funds have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. grew its stake in R1 RCM by 40.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,171,275 shares of the healthcare provider’s stock valued at $17,651,000 after buying an additional 338,507 shares in the last quarter. Rhumbline Advisers grew its stake in R1 RCM by 22.1% in the 3rd quarter. Rhumbline Advisers now owns 544,321 shares of the healthcare provider’s stock valued at $8,203,000 after buying an additional 98,503 shares in the last quarter. Invesco Ltd. grew its stake in R1 RCM by 4.4% in the 3rd quarter. Invesco Ltd. now owns 5,120,817 shares of the healthcare provider’s stock valued at $77,171,000 after buying an additional 218,100 shares in the last quarter. Hsbc Holdings PLC grew its stake in R1 RCM by 14.8% in the 3rd quarter. Hsbc Holdings PLC now owns 285,497 shares of the healthcare provider’s stock valued at $4,305,000 after buying an additional 36,803 shares in the last quarter. Finally, Mariner LLC grew its stake in R1 RCM by 10.6% in the 3rd quarter. Mariner LLC now owns 29,508 shares of the healthcare provider’s stock valued at $445,000 after buying an additional 2,836 shares in the last quarter. Institutional investors own 61.10% of the company’s stock.

R1 RCM Stock Down 0.6 %

Shares of NASDAQ:RCM opened at $12.56 on Monday. The firm has a market cap of $5.29 billion, a P/E ratio of -157.00 and a beta of 0.86. The company has a quick ratio of 1.79, a current ratio of 1.79 and a debt-to-equity ratio of 0.78. R1 RCM has a 12-month low of $8.87 and a 12-month high of $18.70. The business has a fifty day simple moving average of $12.39 and a 200 day simple moving average of $11.81.

R1 RCM (NASDAQ:RCM) last announced its earnings results on Wednesday, May 8th. The healthcare provider reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.03). R1 RCM had a negative return on equity of 1.16% and a negative net margin of 1.39%. The company had revenue of $603.90 million for the quarter, compared to the consensus estimate of $612.88 million. The firm’s quarterly revenue was up 10.7% on a year-over-year basis. Analysts predict that R1 RCM will post -0.17 earnings per share for the current year.

About R1 RCM

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.